Outcomes among venous thromboembolism patients who were admitted into the emergency department and treated with apixaban or warfarin in the U.S. (VTE CER in Premier ED)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/34961
• EU PAS number:
  EUPAS29963
• Study ID:
  34961
• Official title and acronym:
  Outcomes among venous thromboembolism patients who were admitted into the emergency department and treated with apixaban or warfarin in the U.S. (VTE CER in Premier ED)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This study will evaluate real-world outcomes among patients with VTE admitted into the emergency department and treated with either apixaban or warfarin.
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Actual: 02/01/2019

Study start date

Planned: 26/06/2019

Actual: 26/06/2019

Date of final study report

Planned: 20/06/2020

Actual: 06/04/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer

Study protocol

Initial protocol

PremierDB_Hospital_VTE_ED_Protocol_vfinal

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable